Published in J Clin Endocrinol Metab on November 23, 2011
Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J Am Coll Cardiol (2013) 1.58
NH2-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes (2013) 1.35
Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest (2012) 1.32
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J (2012) 1.24
Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. JACC Heart Fail (2013) 1.05
The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis. Metabolism (2013) 1.01
Atrial natriuretic peptide and adiponectin interactions in man. PLoS One (2012) 0.92
Genetics of new-onset diabetes after transplantation. J Am Soc Nephrol (2013) 0.90
Prospective evaluation of B-type natriuretic peptide concentrations and the risk of type 2 diabetes in women. Clin Chem (2013) 0.84
Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene (2015) 0.84
Impaired atrial natriuretic peptide-mediated lipolysis in obesity. Int J Obes (Lond) (2015) 0.83
Natriuretic Peptides and Cardiometabolic Health. Circ J (2015) 0.79
Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc (2015) 0.78
Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Metab (2015) 0.78
A genetic variant of the atrial natriuretic peptide gene is associated with left ventricular hypertrophy in a non-diabetic population--the Malmö preventive project study. BMC Med Genet (2013) 0.78
Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia (2014) 0.78
Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events. J Am Heart Assoc (2015) 0.78
Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study. Metabolism (2016) 0.75
Association between serum soluble corin and hyperglycaemia: a cross-sectional study among Chinese adults. BMJ Open (2015) 0.75
Computerized tomography measured liver fat is associated with low levels of N-terminal pro-brain natriuretic protein (NT-proBNP). Multi-Ethnic Study of Atherosclerosis. Metabolism (2016) 0.75
Pharmacogenetics of posttransplant diabetes mellitus. Pharmacogenomics J (2017) 0.75
Atrial natriuretic peptide and type 2 diabetes development--biomarker and genotype association study. PLoS One (2014) 0.75
Cardiac natriuretic peptides: contributors to cardiac cachexia or possible anti-obesity agents or both? Diabetes (2012) 0.75
INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocr Connect (2015) 0.75
NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study. Cardiovasc Diabetol (2017) 0.75
Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med (2005) 15.30
Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care (2000) 9.10
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest (1996) 6.38
Natriuretic peptides. N Engl J Med (1998) 6.04
Impact of obesity on plasma natriuretic peptide levels. Circulation (2004) 4.46
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81
Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science (1995) 3.61
Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature (1995) 2.90
Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol (2007) 2.21
Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology (1992) 2.06
Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes (2009) 2.03
Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation (2007) 1.93
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation (2004) 1.81
Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A (1996) 1.81
Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem (2004) 1.80
Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes (2002) 1.70
Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One (2010) 1.53
Plasma copeptin and the risk of diabetes mellitus. Circulation (2010) 1.44
Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes (2005) 1.42
Biochemistry of natriuretic peptides. J Intern Med (1994) 1.37
N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension (2005) 1.31
Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia (1998) 1.31
Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens (1997) 1.26
Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation (2004) 1.23
Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia (2007) 1.13
Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta (2001) 1.06
Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med (2005) 1.02
Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem (2004) 1.02
Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 0.97
Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J Cardiovasc Pharmacol (1987) 0.95
Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol (2009) 0.93
Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance. Diabetes Obes Metab (2003) 0.92
Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care (2011) 0.87
Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertens (2007) 0.87
Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets. Peptides (1996) 0.86
Minisymposium: The Malmö Diet and Cancer Study. Design, biological bank and biomarker programme. 23 October 1991, Malmo, Sweden. J Intern Med (1993) 0.86
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature (2010) 12.07
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet (2008) 9.39
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med (2008) 8.70
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics (2005) 7.13
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics (2008) 6.45
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15
A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA (2009) 5.22
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest (2007) 5.02
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA (2004) 4.85
Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet (2008) 4.84
Conserved noncoding sequences are selectively constrained and not mutation cold spots. Nat Genet (2005) 4.79
Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA (2004) 4.63
A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med (2008) 4.61
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation (2005) 4.08
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet (2009) 3.81
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation (2009) 3.55
Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem (2005) 3.55
Long-term trends in the incidence of heart failure after myocardial infarction. Circulation (2008) 3.52
Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2006) 3.48